SPECIALTY GUIDELINE MANAGEMENT

NEULASTA (pegfilgrastim)
FULPHILA (pegfilgrastim-jmdp)
NYVEPRIA (pegfilgrastim-apgf)
UDENYCA (pegfilgrastim-cbqv)
ZIEXTENZO (pegfilgrastim-bmez)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indication

Neulasta
1. Patients with Cancer Receiving Myelosuppressive Chemotherapy
   Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
2. Hematopoietic Syndrome of Acute Radiation Syndrome
   Neulasta is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).

Fulphila
Patients with Cancer Receiving Myelosuppressive Chemotherapy
Fulphila is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia

Udenyca
Patients with Cancer Receiving Myelosuppressive Chemotherapy
Udenyca is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Ziextenzo
Patients with Cancer Receiving Myelosuppressive Chemotherapy
Ziextenzo is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use: Ziextenzo is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
**Nyvepria**

Patients with Cancer Receiving Myelosuppressive Chemotherapy

Nyvepria is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

*Limitations of Use: Nyvepria is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.*

**B. Compendial Use**

1. Stem cell transplantation-related indications
2. Prophylaxis for chemotherapy-induced febrile neutropenia in patients with solid tumors
3. Hematopoietic Syndrome of Acute Radiation Syndrome
4. Hairy cell leukemia
5. Chronic Myeloid Leukemia (CML), treatment of persistent neutropenia due to tyrosine kinases inhibitor therapy

All other indications are considered experimental/investigational and not medically necessary.

**II. REQUIRED DOCUMENTATION**

**Primary Prophylaxis of Febrile Neutropenia**

Documentation must be provided of the member’s diagnosis and chemotherapeutic regimen.

**III. CRITERIA FOR INITIAL APPROVAL**

**A. Prevention of neutropenia in cancer patients receiving myelosuppressive chemotherapy**

Authorization of 6 months may be granted for prevention of febrile neutropenia when all of the following criteria are met (1, 2, 3, and 4):

1. The requested medication will not be used in combination with other colony stimulating factors within any chemotherapy cycle.
2. The member will not be receiving concurrent chemotherapy and radiation therapy.
3. The requested medication will not be administered with weekly chemotherapy regimens.
4. One of the following criteria is met (i or ii):
   i. The requested medication will be used for primary prophylaxis in members with a solid tumor or non-myeloid malignancies who have received, are currently receiving, or will be receiving myelosuppressive anti-cancer therapy that is expected to result in 20% or higher incidence of febrile neutropenia (FN) *(See Appendix A)* OR 10 – 19% risk of FN *(See Appendix B).*
   ii. The requested medication will be used for secondary prophylaxis in members with solid tumors or non-myeloid malignancies who experienced a febrile neutropenic complication or a dose-limiting neutropenic event (a nadir or day of treatment count impacting the planned dose of chemotherapy) from a prior cycle of similar chemotherapy, with the same dose and scheduled planned for the current cycle (for which primary prophylaxis was not received).

**B. Other indications**

Authorization of 6 months may be granted for members with any of the following indications:

1. Stem cell transplantation-related indications
2. Hematopoietic Syndrome of Acute Radiation Syndrome
   Treatment for radiation-induced myelosuppression following a radiological/nuclear incident
3. Hairy cell leukemia
Members with hairy cell leukemia with neutropenic fever following chemotherapy

4. Chronic Myeloid Leukemia
Members with chronic myeloid Leukemia (CML) for treatment of persistent neutropenia due to tyrosine kinase inhibitor therapy

IV. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

V. APPENDIX
A. APPENDIX A: Selected Chemotherapy Regimens with an Incidence of Febrile Neutropenia of 20% or Higher*
1. Acute Lymphoblastic Leukemia:
   Select ALL regimens as directed by treatment protocol (see NCCN guidelines ALL)
2. Bladder Cancer:
   i. Dose dense MVAC (methotrexate, vinblastine, doxorubicin, cisplatin)
   ii. CBDCa/Pac (carboplatin, paclitaxel)
3. Bone Cancer:
   i. VAI (vincristine, doxorubicin or dactinomycin, ifosfamide)
   ii. VDC-IE (vincristine, doxorubicin or dactinomycin, and cyclophosphamide alternating with ifosfamide and etoposide)
   iii. Cisplatin/doxorubicin
   iv. VDC (cyclophosphamide, vincristine, doxorubicin or dactinomycin)
   v. VIDE (vincristine, ifosfamide, doxorubicin or dactinomycin, etoposide)
4. Breast Cancer:
   i. Docetaxel + trastuzumab
   ii. Dose-dense AC (doxorubicin, cyclophosphamide) + paclitaxel (or dose dense paclitaxel)
   iii. TAC (docetaxel, doxorubicin, cyclophosphamide)
   iv. AT (doxorubicin, docetaxel)
   v. Doc (docetaxel)
   vi. TC (docetaxel, cyclophosphamide)
   vii. TCH (docetaxel, carboplatin, trastuzumab)
5. Colorectal Cancer:
   FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, irinotecan)
6. Esophageal and Gastric Cancers:
   Docetaxel/cisplatin/fluorouracil
7. Head and Neck Squamous Cell Carcinoma:
   TPF (docetaxel, cisplatin, 5-fluorouracil)
8. Hodgkin Lymphoma:
   i. Brentuximab vedotin + AVD (doxorubicin, vinblastine, dacarbazine)
   ii. Escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)
9. Kidney Cancer:
   Doxorubicin/gemcitabine
10. Non-Hodgkin’s Lymphoma:
   i. Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)
   ii. ICE (ifosfamide, carboplatin, etoposide)
   iii. Dose-dense CHOP-14 (cyclophosphamide, doxorubicin, vincristine, prednisone) ± rituximab
iv. MINE (mesna, ifosfamide, mitoxantrone, etoposide)
v. DHAP (dexamethasone, cisplatin, cytarabine)
vi. ESHAP (etoposide, methylprednisolone, cisplatin, cytarabine (Ara-C))
rvii. HyperCVAD ± rituximab (cyclophosphamide, vincristine, doxorubicin, dexamethasone ± rituximab)
viii. VAPEC-B (vincristine, doxorubicin, prednisolone, etoposide, cyclophosphamide, bleomycin)

11. Melanoma:
   Dacarbazine-based combination with IL-2, interferon alpha (dacarbazine, cisplatin, vinblastine, IL-2, interferon alfa)

12. Multiple myeloma:
   i. VTD-PACE (dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide + bortezomib)
   ii. DT-PACE (dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide)

13. Ovarian Cancer:
   i. Topotecan
   ii. Docetaxel

14. Pancreatic Cancer:
   FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin)

15. Soft Tissue Sarcoma:
   i. MAID (mesna, doxorubicin, ifosfamide, dacarbazine)
   ii. Doxorubicin
   iii. Ifosfamide/doxorubicin

16. Small Cell Lung Cancer:
   i. Top (topotecan)
   ii. CAV (cyclophosphamide, doxorubicin, vincristine)

17. Testicular cancer:
   i. VelP (vinblastine, ifosfamide, cisplatin)
   ii. VIP (etoposide, ifosfamide, cisplatin)
   iii. TIP (paclitaxel, ifosfamide, cisplatin)

*Applies to chemotherapy regimens with or without monoclonal antibodies (e.g., trastuzumab, rituximab)

B. APPENDIX B: Selected Chemotherapy Regimens with an Incidence of Febrile Neutropenia of 10% to 19%*

1. Occult primary – adenocarcinoma:
   Gemcitabine/docetaxel

2. Breast cancer:
   i. Docetaxel
   ii. CMF classic (cyclophosphamide, methotrexate, fluorouracil)
   iii. CA (doxorubicin, cyclophosphamide) (60 mg/m2) (hospitalized)
   iv. AC (doxorubicin, cyclophosphamide) + sequential docetaxel (taxane portion only)
   v. AC + sequential docetaxel + trastuzumab
   vi. A (doxorubicin) (75 mg/m2)  
   vii. AC (doxorubicin, cyclophosphamide)
   viii. CapDoc (capecitabine, docetaxel)
   ix. Paclitaxel every 21 days

3. Cervical Cancer:
   i. Irinotecan
   ii. Cisplatin/topotecan
   iii. Paclitaxel/cisplatin
   iv. Topotecan
4. Colorectal Cancer:
   i. FL (fluorouracil, leucovorin)
   ii. CPT-11 (irinotecan) (350 mg/m2 q 3 wk)
   iii. FOLFOX (fluorouracil, leucovorin, oxaliplatin)
5. Esophageal and Gastric Cancers:
   i. Irinotecan/cisplatin
   ii. Epirubicin/cisplatin/5-fluorouracil
   iii. Epirubicin/cisplatin/capecitabine
6. Non-Hodgkin’s lymphomas:
   i. EPOCH-IT chemotherapy
   ii. GDP (gemcitabine, dexamethasone, cisplatin/carboplatin)
   iii. GDP (gemcitabine, dexamethasone, cisplatin/carboplatin) + rituximab
   iv. FMR (fludarabine, mitoxantrone, rituximab)
   v. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) including regimens with pegylated liposomal doxorubicin
   vi. CHOP + rituximab (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) including regimens with pegylated liposomal doxorubicin
   vii. CHP (cyclophosphamide, doxorubicin, prednisone) + brentuximab vedotin
   viii. Bendamustine
7. Non-Small Cell Lung Cancer:
   i. Cisplatin/paclitaxel
   ii. Cisplatin/vinorelbine
   iii. Cisplatin/docetaxel
   iv. Cisplatin/etoposide
   v. Carboplatin/paclitaxel
   vi. Docetaxel
8. Ovarian cancer:
   Carboplatin/docetaxel
9. Prostate cancer:
   Cabazitaxel
10. Small Cell Lung Cancer:
    Etoposide/carboplatin
11. Testicular Cancer:
    i. BEP (bleomycin, etoposide, cisplatin)
    ii. Etoposide/cisplatin
12. Uterine sarcoma:
    Docetaxel

*Applies to chemotherapy regimens with or without monoclonal antibodies (e.g., trastuzumab, rituximab)

VI. REFERENCES